bin kontan As it opened for the first time on Nasdaq earlier Friday, shares of Septerna ( NASDAQ: SEPN ) started at $23.50, above the IPO price of $18. The pharma's lead candidate is SEP-786, a PTH1R agonist in phase 1 for hypoparathyroidism.
In a prior SEC filing, Septerna said it planned to offer ~11M shares at $15-$17 a share. At that price, the company expected an IPO of $175M. More on Septerna Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline Septerna proposes terms for upsized $175M IPO IPO Roundup: KinderCare Learnings, Moove and more Financial information for Septerna, Inc.
.
